Eylea Injection contains Aflibercept, a recombinant fusion protein that acts as a VEGF inhibitor. It is administered intravitreal (directly into the eye) to treat retinal conditions that cause abnormal blood vessel growth and fluid leakage, leading to vision loss. Eylea is approved for managing: Wet Age-Related Macular Degeneration (AMD) Diabetic Macular Edema (DME) Diabetic Retinopathy (DR) Macular Edema following Retinal Vein Occlusion (RVO) Retinopathy of Prematurity (ROP) in infants It works by binding to VEGF-A and PlGF, preventing them from stimulating unwanted blood vessel formation. Treatment typically begins with monthly injections, followed by maintenance doses every 2 months, depending on the condition and response.
